Jasper Logo.png
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023 16:51 ET | Jasper Therapeutics
REDWOOD CITY, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on the development of briquilimab, a novel antibody...
Jasper Logo.png
Jasper Therapeutics Strengthens Management Team with Key Appointments
August 02, 2023 08:00 ET | Jasper Therapeutics
Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE...
Jasper Logo.png
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome
June 22, 2023 08:00 ET | Jasper Therapeutics
REDWOOD CITY, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Logo.png
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
June 20, 2023 08:00 ET | Jasper Therapeutics
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees ...
Jasper Logo.png
Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
June 13, 2023 08:00 ET | Jasper Therapeutics
Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board and as Senior Clinical Advisor ...
Jasper Logo.png
Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board
May 10, 2023 08:00 ET | Jasper Therapeutics
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Logo.png
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
April 13, 2023 08:00 ET | Jasper Therapeutics
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Logo.png
Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations
April 10, 2023 16:05 ET | Jasper Therapeutics
REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Logo.png
Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
March 31, 2023 08:00 ET | Jasper Therapeutics
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting...
Jasper Logo.png
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
March 23, 2023 08:00 ET | Jasper Therapeutics
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...